K-CAB

GENERIC NAME:

Tegoprazan

FORMULATION:

Each film-Coated tablet contains: Tegoprazan 50.0 mg

INDICATION:

For treatment of Erosive Gastroesophageal Reflux Disease, Non-erosive Gastroesophageal Reflux Disease, and Gastric Ulcer.

Eradication of H.pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis.

STORAGE CONDITIONS:

Store at temperatures not exceeding 30°C.

ADR REPORTING:

For suspected adverse drug reactions, report to the FDA: ww.fda.gov.ph

Patients should seek medical attention immediately at the first sign of any adverse drug reaction.

 

DOSAGE AND ADMINISTRATION:

Adult:

Treatment of Erosive Gastroesophageal Reflux Disease

  • 50 mg once daily for 4 weeks.
  • For patients who do not heal or have persistent symptoms after 4 weeks, additional 4-week treatment may be considered.

Treatment of Non-Erosive Gastroesophageal Reflux Disease

  • 50 mg once daily for 4 weeks.

Treatment of Gastric Ulcer

  • 50 mg once daily for 8 weeks.

Eradication of H.pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis.

  • Patients with H.pylori infection should be treated with eradication therapy. Tegoprazan 50mg, clarithromycin 500m,g, and amoxicillin 1g are orally administered twice daily for 7 days.

K-CAB can be taken without regard to food.

Description

K-CAB

Tegoprazan

The new KID on the Block